Grant of Interim Extension of the Term of U.S. Patent No. 5,593,823; INTERCEPT® Blood System for Plasma, 491-492 [2014-30945]

Download as PDF Federal Register / Vol. 80, No. 3 / Tuesday, January 6, 2015 / Notices tkelley on DSK3SPTVN1PROD with NOTICES Matters To Be Considered: The Committee will receive reports on the progress of the following subcommittees established to help NTIA develop new or revised strategies for responding more efficiently and effectively to fundamental technological, operational, and other trends to continue advancement of delivering spectrum products, services, and solutions that will support the ever-increasing demand for spectrum: 1. Enforcement 2. Transitional Sharing 3. General Occupancy Measurements and Quantification of Federal Spectrum Use 4. Spectrum Management via Databases 5. Federal Access to Non-federal Bands (Bi-Directional Sharing) 6. Spectrum Sharing Cost Recovery Alternatives 7. Industry and Government Collaboration NTIA will post a detailed agenda on its Web site, http://www.ntia.doc.gov/ category/csmac, prior to the meeting. To the extent that the meeting time and agenda permit, any member of the public may speak to or otherwise address the Committee regarding the agenda items. See Open Meeting and Public Participation Policy, available at http://www.ntia.doc.gov/category/ csmac. Time and Date: The meeting will be held on February 18, 2015, from 1:00 p.m. to 4:00 p.m., Eastern Standard Time. The times and the agenda topics are subject to change. The meeting will be available via two-way audio link and may be webcast. Please refer to NTIA’s Web site, http://www.ntia.doc.gov/ category/csmac, for the most up-to-date meeting agenda and access information. Place: The meeting will be held at the Raytheon Company, 1100 Wilson Boulevard, 20th Floor, Rosslyn, VA 22209–2249. Public comments may be mailed to Commerce Spectrum Management Advisory Committee, National Telecommunications and Information Administration, 1401 Constitution Avenue NW., Room 4099, Washington, DC 20230. The meeting will be open to the public and press on a first-come, first-served basis. Space is limited. All visitors, especially Foreign National Visitors, must send a written request to participate in the meeting on site. Visit request must be provided to Mr. Washington at BWashington@ ntia.doc.gov no later than February 6, 2015. The public meeting is physically accessible to people with disabilities. Individuals requiring accommodations, such as sign language interpretation or other ancillary aids, are asked to notify VerDate Sep<11>2014 19:38 Jan 05, 2015 Jkt 235001 Mr. Washington at (202) 482–6415 or BWashington@ntia.doc.gov at least ten (10) business days before the meeting. Status: Interested parties are invited to attend and to submit written comments to the Committee at any time before or after the meeting. Parties wishing to submit written comments for consideration by the Committee in advance of a meeting must send them to NTIA’s Washington, DC office at the above-listed address and comments must be received five (5) business days before the scheduled meeting date, to provide sufficient time for review. Comments received after this date will be distributed to the Committee, but may not be reviewed prior to the meeting. It would be helpful if paper submissions also include a compact disc (CD) in Word or PDF format. CDs should be labeled with the name and organizational affiliation of the filer. Alternatively, comments may be submitted electronically to BWashington@ntia.doc.gov. Comments provided via electronic mail also may be submitted in one or more of the formats specified above. Records: NTIA maintains records of all Committee proceedings. Committee records are available for public inspection at NTIA’s Washington, DC office at the address above. Documents including the Committee’s charter, member list, agendas, minutes, and any reports are available on NTIA’s Committee Web page at http:// www.ntia.doc.gov/category/csmac. Dated: December 30, 2014. Kathy D. Smith, Chief Counsel, National Telecommunications and Information Administration. [FR Doc. 2014–30872 Filed 1–5–15; 8:45 am] BILLING CODE 3510–60–P DEPARTMENT OF COMMERCE United States Patent and Trademark Office [Docket No.: PTO–P–2014–0068] Grant of Interim Extension of the Term of U.S. Patent No. 5,593,823; INTERCEPT® Blood System for Plasma United States Patent and Trademark Office, Commerce. ACTION: Notice of interim patent term extension. AGENCY: The United States Patent and Trademark Office has issued an order granting a second interim extension under 35 U.S.C. 156(d)(5) for a one-year interim extension of the term of U.S. Patent No. 5,593,823. SUMMARY: PO 00000 Frm 00011 Fmt 4703 Sfmt 4703 491 FOR FURTHER INFORMATION CONTACT: Mary C. Till by telephone at (571) 272– 7755; by mail marked to her attention and addressed to the Commissioner for Patents, Mail Stop Hatch-Waxman PTE, P.O. Box 1450, Alexandria, VA 22313– 1450; by fax marked to her attention at (571) 273–7755; or by email to Mary.Till@uspto.gov. Section 156 of Title 35, United States Code, generally provides that the term of a patent may be extended for a period of up to five years if the patent claims a product, or a method of making or using a product, that has been subject to certain defined regulatory review, and that the patent may be extended for interim periods of up to one year if the regulatory review is anticipated to extend beyond the expiration date of the patent. On December 5, 2014, Cerus Corporation, the patent owner of record, timely filed an application under 35 U.S.C. 156(d)(5) for a second interim extension of the term of U.S. Patent No. 5,593,823. The patent claims the medical device INTERCEPT® Blood System for Plasma. The application indicates that a Premarket Approval Application (PMA) was submitted to the Food and Drug Administration (FDA) in four modules. The PMA Shell number BM120078 was assigned on December 5, 2012. The first module was received by the FDA on March 1, 2013, the second module was received on June 3, 2013, by the FDA, the third module was received by the FDA on September 3, 2013, and the fourth module was received by the FDA on November 29, 2013. The medical device is currently undergoing regulatory review before the FDA for permission to market or use the product commercially. Review of the application indicates that, except for permission to market or use the product commercially, the subject patent would be eligible for an extension of the patent term under 35 U.S.C. 156, and that the patent should be extended for one year as required by 35 U.S.C. 156(d)(5)(B). Because it is apparent that the regulatory review period will continue beyond the extended expiration date of the patent, January 14, 2015, interim extension of the patent term under 35 U.S.C. 156(d)(5) is appropriate. An interim extension under 35 U.S.C. 156(d)(5) of the term of U.S. Patent No. 5,593,823 is granted for a period of one year from the extended expiration date of the patent. SUPPLEMENTARY INFORMATION: E:\FR\FM\06JAN1.SGM 06JAN1 492 Federal Register / Vol. 80, No. 3 / Tuesday, January 6, 2015 / Notices Dated: December 23, 2014. Andrew Hirshfeld, Deputy Commissioner for Patent Examination Policy United States Patent and Trademark Office. [FR Doc. 2014–30945 Filed 1–5–15; 8:45 am] BILLING CODE 3510–16–P COMMODITY FUTURES TRADING COMMISSION Agency Information Collection Activities Under OMB Review Commodity Futures Trading Commission. ACTION: Notice. AGENCY: In compliance with the Paperwork Reduction Act of 1995 (PRA), this notice announces that the Information Collection Request (ICR) abstracted below has been forwarded to the Office of Management and Budget (OMB) for review and comment. The ICR describes the nature of the information collection and its expected costs and burden. DATES: Comments must be submitted on or before February 5, 2014. ADDRESSES: Comments may be submitted directly to the Office of Information and Regulatory Affairs (OIRA) in OMB, within 30 days of the notice’s publication, by email at OIRAsubmissions@omb.eop.gov. Please identify comments by ‘‘Financial Resource Reporting Requirements for Derivatives Clearing Organizations (OMB Control No. 3038–0066).’’ Please provide the Commission with a copy of all submitted comments at the address listed below. Comments may also be mailed to the Office of Information and Regulatory Affairs, Office of Management and Budget, Attention: Desk Officer for the Commodity Futures Trading Commission, 725 17th Street NW., Washington, DC 20503, and Eileen Chotiner, Division of Clearing and Risk, Commodity Futures Trading Commission, Three Lafayette Centre, 1155 21st Street NW., Washington, DC 20581. Comments may be also be submitted, regarding the burden estimated or any other aspect of the information collection, including suggestions for reducing the burden, identified by ‘‘Financial Resource Requirements for Derivatives Clearing Organizations tkelley on DSK3SPTVN1PROD with NOTICES SUMMARY: VerDate Sep<11>2014 19:38 Jan 05, 2015 Jkt 235001 (OMB Control No. 3038–0066),’’ by any of the following methods: • Agency Web site, via its Comments Online process: http:// comments.cftc.gov. Follow the instructions for submitting comments through the Web site. • Mail: Send to Christopher Kirkpatrick, Secretary of the Commission, Commodity Futures Trading Commission, Three Lafayette Centre, 1155 21st Street NW., Washington, DC 20581. • Hand Delivery/Courier: Same as Mail, above. • Federal eRulemaking Portal: http:// www.regulations.gov. Follow the instructions for submitting comments. All comments must be submitted in English or, if not, accompanied by an English translation. Comments will be posted as received to http:// www.cftc.gov. You should submit only information that you wish to make available publicly. If you wish the Commission to consider information that is exempt from disclosure under the Freedom of Information Act, a petition for confidential treatment of the exempt information may be submitted according to the procedures set forth in § 145.9 of the Commission’s regulations. The Commission reserves the right, but shall have no obligation, to review, pre-screen, filter, redact, refuse or remove any or all of your submission from www.cftc.gov that it may deem to be inappropriate for publication, such as obscene language. All submissions that have been redacted or removed that contain comments on the merits of this matter will be retained in the public comment file and will be considered as required under applicable laws. FOR FURTHER INFORMATION CONTACT: Eileen Chotiner, Division of Clearing and Risk, Commodity Futures Trading Commission, Three Lafayette Centre, 1155 21st Street NW., Washington, DC 20581; (202) 418–5467; email: echotiner@cftc.gov, and refer to OMB Control number 3038–0066. This contact can also provide a copy of the ICR. SUPPLEMENTARY INFORMATION: This is a request for extension of a currently approved information collection. Title: ‘‘Financial Resource Reporting Requirements for Derivatives Clearing Organizations (OMB Control No. 3038– 0066).’’ PO 00000 Frm 00012 Fmt 4703 Sfmt 4703 Abstract: Part 39 of the Commission’s regulations establishes financial reporting requirements for derivatives clearing organizations (DCOs), which are required to be registered with the Commission. The Commission will use the information in the reports to assess the DCOs’ compliance with the financial resource requirements for DCOs prescribed in the Commodity Exchange Act and Commission regulations. Burden Statement: The respondent burden for this collection is estimated to average 10 hours per response. Respondents/Affected Entities: Derivatives clearing organizations. Estimated Number of Respondents: 14. Estimated Total Annual Burden on Respondents: 560 hours. Frequency of Collection: Quarterly and on occasion. Authority: 44 U.S.C. 3501 et seq. Dated: December 31, 2014. Christopher J. Kirkpatrick, Secretary of the Commission. [FR Doc. 2014–30950 Filed 1–5–15; 8:45 am] BILLING CODE 6351–01–P DEPARTMENT OF DEFENSE Office of the Secretary [Transmittal Nos. 13–45] 36(b)(1) Arms Sales Notification Defense Security Cooperation Agency, Department of Defense. ACTION: Notice. AGENCY: The Department of Defense is publishing the unclassified text of a section 36(b)(1) arms sales notification. This is published to fulfill the requirements of section 155 of Public Law 104–164 dated July 21, 1996. FOR FURTHER INFORMATION CONTACT: Ms. B. English, DSCA/DBO/CFM, (703) 601– 3740. The following is a copy of a letter to the Speaker of the House of Representatives, Transmittals 13–45 with attached transmittal, policy justification, and Sensitivity of Technology. SUMMARY: Dated: December 31, 2014. Aaron Siegel, Alternate OSD Federal Register Liaison Officer, Department of Defense. E:\FR\FM\06JAN1.SGM 06JAN1

Agencies

[Federal Register Volume 80, Number 3 (Tuesday, January 6, 2015)]
[Notices]
[Pages 491-492]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-30945]


-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

[Docket No.: PTO-P-2014-0068]


Grant of Interim Extension of the Term of U.S. Patent No. 
5,593,823; INTERCEPT[supreg] Blood System for Plasma

AGENCY: United States Patent and Trademark Office, Commerce.

ACTION: Notice of interim patent term extension.

-----------------------------------------------------------------------

SUMMARY: The United States Patent and Trademark Office has issued an 
order granting a second interim extension under 35 U.S.C. 156(d)(5) for 
a one-year interim extension of the term of U.S. Patent No. 5,593,823.

FOR FURTHER INFORMATION CONTACT: Mary C. Till by telephone at (571) 
272-7755; by mail marked to her attention and addressed to the 
Commissioner for Patents, Mail Stop Hatch-Waxman PTE, P.O. Box 1450, 
Alexandria, VA 22313-1450; by fax marked to her attention at (571) 273-
7755; or by email to Mary.Till@uspto.gov.

SUPPLEMENTARY INFORMATION: Section 156 of Title 35, United States Code, 
generally provides that the term of a patent may be extended for a 
period of up to five years if the patent claims a product, or a method 
of making or using a product, that has been subject to certain defined 
regulatory review, and that the patent may be extended for interim 
periods of up to one year if the regulatory review is anticipated to 
extend beyond the expiration date of the patent.
    On December 5, 2014, Cerus Corporation, the patent owner of record, 
timely filed an application under 35 U.S.C. 156(d)(5) for a second 
interim extension of the term of U.S. Patent No. 5,593,823. The patent 
claims the medical device INTERCEPT[supreg] Blood System for Plasma. 
The application indicates that a Premarket Approval Application (PMA) 
was submitted to the Food and Drug Administration (FDA) in four 
modules. The PMA Shell number BM120078 was assigned on December 5, 
2012. The first module was received by the FDA on March 1, 2013, the 
second module was received on June 3, 2013, by the FDA, the third 
module was received by the FDA on September 3, 2013, and the fourth 
module was received by the FDA on November 29, 2013. The medical device 
is currently undergoing regulatory review before the FDA for permission 
to market or use the product commercially.
    Review of the application indicates that, except for permission to 
market or use the product commercially, the subject patent would be 
eligible for an extension of the patent term under 35 U.S.C. 156, and 
that the patent should be extended for one year as required by 35 
U.S.C. 156(d)(5)(B). Because it is apparent that the regulatory review 
period will continue beyond the extended expiration date of the patent, 
January 14, 2015, interim extension of the patent term under 35 U.S.C. 
156(d)(5) is appropriate.
    An interim extension under 35 U.S.C. 156(d)(5) of the term of U.S. 
Patent No. 5,593,823 is granted for a period of one year from the 
extended expiration date of the patent.


[[Page 492]]


    Dated: December 23, 2014.
Andrew Hirshfeld,
Deputy Commissioner for Patent Examination Policy United States Patent 
and Trademark Office.
[FR Doc. 2014-30945 Filed 1-5-15; 8:45 am]
BILLING CODE 3510-16-P